SPRO

Spero Therapeutics Inc

SPRO, USA

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

https://sperotherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SPRO
stock
SPRO

Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Buy" at Wall Street Zen MarketBeat

Read more →
SPRO
stock
SPRO

Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$4

Analyst Picks

Strong Buy

0

Buy

1

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.93

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-27.86 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-13.63 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

571.59 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.04

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 24.52% of the total shares of Spero Therapeutics Inc

1.

Pfizer Inc

(4.1978%)

since

2025/06/30

2.

Vanguard Group Inc

(3.4658%)

since

2025/06/30

3.

Anson Funds Management LP

(2.8707%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(2.0274%)

since

2025/07/31

5.

Alphabet Inc

(1.5815%)

since

2025/06/30

6.

Renaissance Technologies Corp

(1.4787%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9171%)

since

2025/07/31

8.

Schonfeld Strategic Advisors LLC

(0.9077%)

since

2025/06/30

9.

Geode Capital Management, LLC

(0.9075%)

since

2025/06/30

10.

BlackRock Inc

(0.7726%)

since

2025/06/30

11.

MONIMUS CAPITAL MANAGEMENT, LP

(0.5525%)

since

2025/06/30

12.

IMC US Ultra Micro Cap

(0.4537%)

since

2025/07/31

14.

Fidelity Extended Market Index

(0.42%)

since

2025/07/31

15.

Stonepine Capital Management Llc

(0.2788%)

since

2025/06/30

16.

State Street Corp

(0.2727%)

since

2025/06/30

17.

Ionic Capital Management LLC

(0.2665%)

since

2025/06/30

18.

ADAR1 Capital Management LLC

(0.2557%)

since

2025/06/30

19.

Pleiades Small Cap Equity A

(0.2269%)

since

2025/06/30

20.

Bridgeway Capital Management, LLC

(0.204%)

since

2025/06/30

21.

Fidelity Total Market Index

(0.1933%)

since

2025/07/31

22.

Extended Equity Market Fund K

(0.1903%)

since

2025/06/30

23.

Citadel Advisors Llc

(0.1844%)

since

2025/06/30

24.

Northern Trust Corp

(0.1792%)

since

2025/06/30

25.

Susquehanna International Group, LLP

(0.1241%)

since

2025/06/30

26.

Bridgeway Ultra-Small Company Market

(0.1151%)

since

2025/06/30

27.

JPM Multi-Manager Alt C (acc) USD

(0.1073%)

since

2025/07/31

28.

Fidelity Series Total Market Index

(0.106%)

since

2025/07/31

29.

Spartan Extended Market Index Pool F

(0.0966%)

since

2025/07/31

30.

Northern Trust Extended Eq Market Idx

(0.0889%)

since

2025/06/30

31.

NT Ext Equity Mkt Idx Fd - L

(0.0889%)

since

2025/06/30

32.

Bridgeway Omni Small-Cap Value N

(0.0888%)

since

2025/06/30

33.

Bridgeway Omni Small-Cap Value

(0.0888%)

since

2025/06/30

34.

Avantis US Small Cap Equity ETF

(0.0676%)

since

2025/08/30

35.

XTX Topco Ltd

(0.0614%)

since

2025/06/30

36.

Spartan Total Market Index Pool G

(0.0579%)

since

2025/07/31

37.

Axxcess Wealth Management, LLC

(0.0578%)

since

2025/06/30

38.

Schwab Total Stock Market Index

(0.0508%)

since

2025/07/31

39.

NT Ext Equity Mkt Idx Fd - NL

(0.0465%)

since

2025/06/30

40.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.0406%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.13

EPS Estimate

-0.39

EPS Difference

0.26

Surprise Percent

66.6667%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(4.5)
Net Net
Possible Net-Net(4.5)
Quality
Moderate Quality(3.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.